GlaxoSmithKline, Shionogi finish HIV clinical study

By Elaine Rigoli

Tampa, Fla., Aug. 14 - GlaxoSmithKline and Shionogi & Co., Ltd. announced that they have completed an initial clinical study in humans with an investigational integrase inhibitor, 364735, which is being developed for the treatment of HIV/AIDS.

Integrase inhibitors are a new class of anti-HIV drugs that block viral replication by preventing the virus from integrating into the genetic material of human immune cells, according to a news release.

A phase 1 study of 364735 was recently conducted in the United States to assess safety and pharmacokinetics in healthy volunteers. Results from this clinical trial will be submitted for presentation at an upcoming medical conference in 2007, the release said.

Data from this study of 364735 have enabled selection of doses for a phase 2 study, the next step in its clinical development, which is planned to start in late 2006 in HIV-infected adults.

GlaxoSmithKline is a pharmaceutical company based in London.

Shionogi is an Osaka, Japan-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.